作者
Jan R Dörr, Yong Yu, Maja Milanovic, Gregor Beuster, Christin Zasada, J Henry M Däbritz, Jan Lisec, Dido Lenze, Anne Gerhardt, Katharina Schleicher, Susanne Kratzat, Bettina Purfürst, Stefan Walenta, Wolfgang Mueller-Klieser, Markus Gräler, Michael Hummel, Ulrich Keller, Andreas K Buck, Bernd Dörken, Lothar Willmitzer, Maurice Reimann, Stefan Kempa, Soyoung Lee, Clemens A Schmitt
发表日期
2013/9/19
期刊
Nature
卷号
501
期号
7467
页码范围
421-425
出版商
Nature Publishing Group UK
简介
Activated oncogenes and anticancer chemotherapy induce cellular senescence, a terminal growth arrest of viable cells characterized by S-phase entry-blocking histone 3 lysine 9 trimethylation (H3K9me3),. Although therapy-induced senescence (TIS) improves long-term outcomes, potentially harmful properties of senescent tumour cells make their quantitative elimination a therapeutic priority. Here we use the Eµ-myc transgenic mouse lymphoma model in which TIS depends on the H3K9 histone methyltransferase Suv39h1 to show the mechanism and therapeutic exploitation of senescence-related metabolic reprogramming in vitro and in vivo. After senescence-inducing chemotherapy, TIS-competent lymphomas but not TIS-incompetent Suv39h1 lymphomas show increased glucose utilization and much higher ATP production. We demonstrate that this is linked to massive proteotoxic stress, which is a …
引用总数
201420152016201720182019202020212022202320244545424956476377585630
学术搜索中的文章